Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Alemtuzumab reported to increase clinical response and remission in refractory CLL

July 8, 2003

Treatment begins in INGN-225 phase I/II study

July 7, 2003

Phase II trial to evaluate Pentrix in prostate cancer

July 4, 2003

Antisoma initiates enrollment in phase I study of R-1550 in breast cancer

July 4, 2003

Preclinical studies support use of MT-103 for chronic lymphocytic leukemia

July 1, 2003

CPMP hands down positive opinion for survival claim for MabCampath

June 30, 2003

Preliminary findings for Ceplene in stage IV malignant melanoma

June 26, 2003

Phase III Theratope vaccine trial fails to meet primary endpoints

June 19, 2003

Interferon alfa variants with enhanced immunomodulatory and antitumor activity

June 17, 2003

Dendreon's phase III trial will serve as basis for Provenge approval

June 17, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...